雷贝拉唑钠/甲硝唑/阿莫西林(Rabeprazole Sodium/Metronidazole/Amoxicillin) - 药物靶点：Proton pump_在研适应症：胃炎，十二指肠溃疡，幽门螺杆菌感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Clofezone、Rabeprazole、Rabeprazole Sodium/Amoxicillin Hydrate/Metronidazole

+ [4]

靶点

Proton pump

作用方式

抑制剂

作用机制

质子泵抑制剂、细胞壁抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

权益机构

Woodward Pharma Services LLC

Eisai Co., Ltd.

最高研发阶段批准上市

首次获批日期

日本 (2013-08-15),

十二指肠溃疡幽门螺杆菌感染免疫性血小板减少症+ [1]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H21N3O6S

InChIKeyAIPFZZHNBUVELL-YWUHCJSESA-N

CAS号61336-70-7

查看全部结构式(3)

关联

79

项与雷贝拉唑钠/甲硝唑/阿莫西林相关的临床试验

ChiCTR2400093507

/ Suspended早期临床1期IIT

The comparative study of the impact of Vonoprazon and Rabeprazole in oral microbial transmission

开始日期2024-12-15

申办/合作机构

浙江大学医学院附属第二医院（浙江省第二医院）

CTIS2023-506305-18-01

/ Recruiting临床1期

- PHA022121-C014

开始日期2024-09-19

申办/合作机构

Pharvaris Netherlands BV

ACTRN12624000878572

/ Completed临床1期

A Phase 1, Fixed Sequence, Open-Label Study to Evaluate the Effect of Multiple Doses of Rabeprazole on the Pharmacokinetics of a Single Dose of Radiprodil in Healthy Adult Participants

开始日期2024-08-26

申办/合作机构

GRIN Therapeutics, Inc.

[+1]

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的临床结果

登录后查看更多信息

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的转化医学

登录后查看更多信息

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的专利（医药）

登录后查看更多信息

1,364

项与雷贝拉唑钠/甲硝唑/阿莫西林相关的文献（医药）

2025-09-01·AMERICAN HEART JOURNAL

Potassium-competitive acid blocker vs proton-pump inhibitor in patients receiving antithrombotic therapy who are at high risk for gastrointestinal bleeding: Rationale and design of the randomized PROTECT- HBR trial

Article

作者: Lee, Jinho ; Park, Hwan-Cheol ; Kim, Byeong-Keuk ; Park, Han-Su ; Kim, Sang Min ; Choi, Kee Don ; Park, Seung-Jung ; Lee, Jong-Young ; Yang, Tae-Hyun ; Jin, Eun-Sun ; Kim, Weon ; Lim, Young-Hyo ; Yoon, Myeong-Ho ; Her, Sung-Ho ; Kim, Sang-Hyun ; Lee, Junghoon ; Lee, Wang Soo ; Park, Hanbit ; Hong, Soon Jun ; Suh, Jung-Won ; Kwon, Sung Uk ; Park, Kyoung-Ha ; Kang, Do-Yoon ; Nam, Chang-Wook ; Shin, Eun-Seok ; Park, Duk-Woo ; Ahn, Jung-Min ; Kang, Se Hun ; Yoon, Yong-Hoon ; Choi, Eue-Keun ; Choi, Young Jin ; Jeong, Jin-Ok

BACKGROUND:

Concomitant use of proton pump inhibitor (PPI) is recommended in patients receiving chronic antithrombotic therapy who are at high risk of gastrointestinal (GI) bleeding. However, long-term safety and efficacy of chronic PPI use have been concerned. Potassium-competitive acid blocker (P-CAB) is a novel class of acid suppressants, providing more acid stability, rapid onset of action, less variability with CYP2C19 polymorphisms, and longer duration of action than PPI.

DESIGN:

The PROTECT-HBR trial is a multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial. Approximately 3320 patients with known cardiac or vascular disease receiving antithrombotic drugs (either antiplatelet or anticoagulant agents) and who are at high risk of GI bleeding will be randomized to P-CAB (tegoprazan 50mg once daily) or PPI (rabeprazole 20mg once daily) for up to 12 months. The primary endpoint is a composite outcome of upper GI clinical events, including overt or occult GI bleeding, symptomatic gastroduodenal ulcers or erosions, obstruction, or perforation, at 12 months. Secondary endpoints also included cardiovascular events and safety outcomes.

RESULTS:

As of December 2024, approximately 1460 patients were enrolled from 32 participating sites in South Korea. The complete enrollment is anticipated at the mid- or late-term of 2025, and the primary results will be available by 2027.

CONCLUSION:

PROTECT-HBR is a large-scale, multicenter, clinical trial, which will provide a pivotal comparison of the efficacy and safety of novel P-CAB, tegoprazan with those of PPI, rabeprazole in patients with documented cardiac or vascular disease receiving chronic antithrombotic drugs and at high risk of GI bleeding.

CLINICAL TRIAL REGISTRATION:

Potassium-Competitive Acid Blocker versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High GastroIntestinal Bleeding Risk Receiving Antithrombotic Therapy (PROTECT-HBR): NCT04416581.

2025-05-12·CURRENT CARDIOLOGY REVIEWS

Antiplatelet-Proton Pump Inhibitor Interactions and Arterial Thrombotic Events: A Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis

Article

作者: Sridharan, Kannan

Aims::

The aim of this study is to evaluate the safety profiles of antiplatelet-proton pump inhibitors (PPIs) combinations and assess the clinical implications of their concurrent use in real-world settings through pharmacovigilance data analysis.

Background::

The concomitant use of PPIs with antiplatelet therapy remains controversial due to potential drug interactions affecting clinical outcomes. While PPIs are recommended for gastroprotection in patients receiving antiplatelet therapy, concerns persist regarding their impact on antiplatelet efficacy, particularly with dual antiplatelet therapy (DAPT).

Objectives::

The objective of this study is to analyze and compare the thrombo-embolic risk profiles of various antiplatelet-PPI combinations using the FDA Adverse Event Reporting System database.

Methods::

We conducted a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database to evaluate the thrombo-embolic risk associated with antiplatelet-PPI combinations. The reporting odds ratio (ROR) and information component were calculated to detect safety signals. The interaction signal score (INTSS) was used to assess the protective or harmful effects of adding acetylsalicylic acid to clopidogrel-PPI combinations.

Results::

Analysis revealed significant safety signals for thrombo-embolic events with clopidogrel-rabeprazole (ROR: 62.67, 95% CI: 38.38-102.32) and clopidogrel-omeprazole (ROR: 6.87, 95% CI: 4.89-9.66) combinations. DAPT-PPI combinations showed comparable safety profiles to monotherapy-PPI combinations. The INTSS analysis suggested a potential protective effect of acetylsalicylic acid when added to clopidogrel-PPI combinations. Genderspecific analysis revealed female predominance in monotherapy complications and male predominance in combination therapy events. Clinical outcomes, including mortality and hospitalization rates, were comparable between groups.

Conclusion::

This pharmacovigilance analysis suggests that while DAPT-PPI combinations demonstrate acceptable safety profiles, careful consideration should be given to PPI selection, particularly given the unexpected safety signals with rabeprazole and confirmed risks with omeprazole. The addition of acetylsalicylic acid to clopidogrel-PPI combinations may offer protective effects against thrombo-embolic events. These findings support individualized riskbenefit assessment in selecting antiplatelet-PPI combinations while ensuring adequate gastroprotection for high-risk patients.

2025-05-01·Pharmacoeconomics-Open

So Many Choices, So Little Value: Potential Savings from Selecting Cost-Effective Proton Pump Inhibitors

Article

作者: Kwon, Hye-Young

BACKGROUND:

Given that Korea lacks measures to promote cost-effective prescribing, this study investigated the efficiency of prescribers' decision-making when faced with the choice of 398 products containing 15 proton pump inhibitors (PPI).

OBJECTIVE:

This study aimed to explore PPI prescribing patterns in ambulatory care over 10 years and elucidate prescribers' practices. Further analysis was conducted to estimate the achievable potential savings, assuming that the recommendation of first-choice drugs is based on the rational use of medicines.

METHODS:

Retrospective PPI prescribing data from the ambulatory sector pertaining to medical services provided to the entire South Korean population from 2013 to 2022 were extracted from the Korean National Health Information Database; the data were analyzed to identify annual trends in PPI spending and utilization volume according to defined daily doses (DDDs). Unit price per DDD was calculated, and a preferred cost-effective choice with identical efficacy and safety profile was selected among PPIs. The potential savings were then simulated using Dirichlet distribution.

RESULTS:

In ambulatory care, PPI drug costs increased by 13.0% per annum over 10 years. The preferred substances were esomeprazole (31.6%), rabeprazole (23.2%), and tegoprazan (16.5%), which are among the most expensive PPIs. However, the most cost-effective substance was dexlansoprazole (South Korean won [KRW] 522.7; standard deviation [SD] = 72.2; and median = 583). If dexlansoprazole is recommended as the first-choice PPI in the Korean context, the estimated cost savings would be 404.24 billion KRW, equivalent to 47.0% of the current PPI spending in ambulatory care.

CONCLUSIONS:

This study identified opportunities for substantial cost savings related to PPI prescribing. Guided decision-making toward cost-effective PPI prescribing would increase the efficiency of prescribing and the sustainability of the healthcare system.

5

项与雷贝拉唑钠/甲硝唑/阿莫西林相关的新闻（医药）

2025-03-29

·ETPharma

103 drug samples fail CDSCO quality test, popular brand Telma H flagged as spurious

New Delhi: During its monthly quality review, the drug regulatory body identified 103 drug samples as ‘Not of Standard Quality’ ( NSQ ) and flagged a sample of the popular brand Telma H as ‘spurious.’ Of the 103 drug samples that failed to meet the quality standards, 47 were identified by central drug laboratories, while the remaining 56 were identified by state drug laboratories in the country. The drug sample that has been labeled as “spurious” is Telma H (Telmisartan 40mg & Hydrochlorothiazide 12.5mg), a popular brand prescribed for high blood pressure patients. As per the Union Health Ministry note, the sample was picked from West Bengal. As per the February drug alert issued by the Central Drugs Standard Control Organisation (CDSCO), the sample was manufactured in 2022 and the reason for the drug test failure as notified in the alert suggests that the sample “does not conform to I.P.” (Indian Pharmacopoeia). The branded generic drug is marketed by Glenmark and, as per an analysis from market research firm Pharmarack, it features among the top 50 brands in the country, with a moving annual total (MAT) value of around ₹447 crore. Regarding the identified spurious drug sample, the Health Ministry, in its quality review announcement, stated that the sample is “made by an unauthorized manufacturer using a brand name owned by another company. The matter is under investigation and action.” CDSCO, in its drug quality alert, has remarked that the product is purported to be spurious; however, the same is subject to the outcome of the investigation. The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The 47 NSQ samples identified by the central laboratories include Rabeprazole Tablets manufactured by Martin & Brown BioSciences Pvt. Ltd.; Paracetamol & Diclofenac Sodium Tablets manufactured by I.G. PHARMA LTD.; and Telmisartan Tablets IP by Orison Pharma International, among 44 others. Whereas, the list from state laboratories comprises Calcium & Vitamin D3 Tablets manufactured by Affy Parenterals Vill.; Phenytoin Tablets by Jackson Laboratories; and Cloprostenol Injection by Monatt Biotech, including 53 others. According to CDSCO, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; if it is an imitation of, or a substitute for, another drug; if it resembles another drug in a manner likely to deceive; or if it bears upon its label or container the name of another drug, among other provisions defined under Section 17-B of the Drugs and Cosmetics Act, 1940. Whereas drugs that fail to meet quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Abhijeet Singh ,

2024-06-13

·Pharmaindustrial

Akums Launches Rabeprazole + Levosulpiride SR Capsules

Akums Drugs & Pharmaceuticals Ltd. announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders. GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer. “Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement. Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed. “We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement. Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

上市批准

2023-12-19

·PRNewswire

Proton Pump Inhibitors (PPIs) Market to grow by USD 807.89 million from 2023-2028 | North America to account for 36% of market growth - Technavio

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- The proton pump inhibitors (PPIs) market size is expected to grow by USD 807.89 million from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 4.86% during the forecast period, according to Technavio Research. The market is categorized by Product (OTC PPIs and Prescription PPIs), Route Of Administration (Oral and Injectable), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America will contribute 36% to the growth of the global market during the forecast period. Factors such as the presence of large pharmaceutical companies that offer both branded and generic PPIs and the presence of a proper regulatory framework for the approval of new drugs in the region drive regional market growth. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a FREE PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global Proton Pump Inhibitors (PPIs) Market 2024-2028 Company Profile: Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., Zydus Lifesciences Ltd. Amgen Inc. - The company offers proton pump inhibitors such as LUMAKRAS with gastric acid-reducing agents and decreased sotorasib concentrations. To gain access to more vendor profiles available with Technavio, buy the report! Proton Pump Inhibitors (PPIs) Market: Health Analysis Proton Pump Inhibitors (PPIs) play a significant role in managing various gastrointestinal conditions, including Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease, and Gastritis, effectively suppressing acid production. Helicobacter pylori, a common bacterium, often contributes to Peptic Ulcer Disease, for which both prescription and non-prescription PPIs are used as part of the treatment regimen, ensuring comprehensive therapy against this bacterial infection. The Proton Pump Inhibitor Market showcases a diverse range of medications, including FDA-approved and generic PPIs, aiming to alleviate symptoms associated with acid-related disorders like Heartburn, Erosive Esophagitis, and NSAID-Induced Ulcers. Understanding the potential side effects of Proton Pump Inhibitors is crucial, as they are associated with complications such as Duodenal Ulcers, necessitating careful consideration of their usage and monitoring for optimal gastrointestinal health. Heartburn, often associated with Acid-related Disorders, manifests as a burning sensation in the chest due to stomach acid reflux into the esophagus. This common symptom occurs post-meals, triggered by specific foods or lying down, contributing significantly to Acid-related Disorders' discomfort. Managing heartburn involves dietary modifications, maintaining an upright posture after eating, and utilizing medications to mitigate stomach acid production. Chronic heartburn, if left unaddressed, may lead to erosive esophagitis or Barrett's esophagus, highlighting its role within Acid-related Disorders and emphasizing the need for prompt intervention to alleviate symptoms and prevent complications. Proton Pump Inhibitors (PPIs) Market: Segmentation Analysis The OTC PPIs segment will be significant during the forecast period. The products in this segment are defined as medicines that are sold directly to patients or consumers without a prescription from a healthcare professional. Furthermore, the availability of OTC PPIs provides patients with an option for self-medication and reduces the financial burden associated with medication treatment. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report These six medications—Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, and Dexlansoprazole—belong to the class of proton pump inhibitors, commonly prescribed to treat various gastrointestinal conditions by reducing stomach acid production. Each drug within this group exhibits distinct pharmacokinetic properties and efficacy profiles, catering to individual patient needs for managing acid-related disorders. "Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio Proton Pump Inhibitors (PPIs) Market: Driver & Trend: Driver Reformulation of drugs Growth in prescription rate Strong prevalence of gastroesophageal reflux disease Reformulation of drugs drives market growth. It provides an opportunity to grab patent term extensions, which can delay the entry of generic versions into the market. The availability of two dosage forms, NEXIUM 10 mg and 20 mg, will increase the consumption of the drug for various indications, particularly acid-related diseases, in both children aged one year and above the older patients with difficulty in swallowing. The rising prevalence of obesity is a leading market trend. Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information. Unraveling Therapeutic Efficacy and Potential Complications in Gastrointestinal Health The Proton Pump Inhibitors (PPIs) Market comprises an extensive range of medications tailored to manage diverse acid-related disorders like Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease, and Gastritis. FDA-approved prescription PPIs play a significant role in treating conditions such as Zollinger-Ellison Syndrome and NSAID-Induced Ulcers, contributing significantly to gastrointestinal health and acid suppression. It's essential to recognize that both non-prescription and generic PPIs exist within this market, each exhibiting distinct efficacy profiles and potential side effects, including complications associated with prolonged use such as erosive esophagitis. Understanding the complexities of these medications is crucial for addressing various conditions and ensuring patient well-being amid the dynamic landscape of Proton Pump Inhibitors (PPIs) Market. Related Reports: The tyrosine kinase inhibitors market is estimated to grow at a CAGR of 8.93% between 2022 and 2027. The market size is forecasted to increase by USD 24.12 billion. The global PARP (poly ADP-ribose polymerase) inhibitors market size is estimated to grow by USD 5,555.99 million at a CAGR of 13.25% between 2023 and 2028. What are the key data covered in this proton pump inhibitors (PPIs) market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the proton pump inhibitors (PPIs) market between 2023 and 2028. Precise estimation of the proton pump inhibitors (PPIs) market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the proton pump inhibitors (PPIs) market across North America, Europe, Asia, and ROW A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of proton pump inhibitors (PPIs) market vendors. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Product Market Segmentation by Route of Administration Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	雷贝拉唑钠/甲硝唑/阿莫西林	J01CR02	DB01129

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胃炎	日本	Eisai Co., Ltd.	2013-11-21
十二指肠溃疡	日本	Eisai Co., Ltd.	2013-08-15
幽门螺杆菌感染	日本	Eisai Co., Ltd.	2013-08-15
免疫性血小板减少症	日本	Eisai Co., Ltd.	2013-08-15
胃溃疡	日本	Eisai Co., Ltd.	2013-08-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床3期	美国	Eisai, Inc.	2002-09-01
胃食管反流	临床3期	美国	Eisai, Inc.	2002-09-01
消化不良	临床2期	日本	Eisai Co., Ltd.	2010-04-01
鼻咽疾病	临床2期	美国	Eisai, Inc.	2002-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


DDW2024	N/A	一线	720	14-day vonoprazan triple therapy	製繭鬱鹹網網遞衊憲醖(窪蓋積選獵醖網鬱齋觸) = 鬱製壓鹹醖艱壓製範衊網襯廠鹹憲膚鹹構鹽簾 (範餘糧齋夢顧積繭淵淵, 90.1 ~ 96.5)	积极	2024-05-18
				14-day vonoprazan high-dose dual therapy	製繭鬱鹹網網遞衊憲醖(窪蓋積選獵醖網鬱齋觸) = 獵蓋簾艱窪糧觸範醖鏇網襯廠鹹憲膚鹹構鹽簾 (範餘糧齋夢顧積繭淵淵, 82.0 ~ 90.6)
NCT02637557 (CTgov)	临床2期	胃食管反流	282	Placebo (Placebo BID)	齋鑰蓋夢糧遞簾顧選壓(蓋簾蓋壓選顧顧鑰選範) = 繭範遞糧遞觸齋廠糧醖鑰範廠膚繭範簾襯憲糧 (夢蓋醖窪遞醖窪簾衊鹹, 4.078) 更多	-	2019-10-15
				IW-3718 (500 mg IW-3718 BID)	齋鑰蓋夢糧遞簾顧選壓(蓋簾蓋壓選顧顧鑰選範) = 夢窪壓壓齋艱夢獵艱鹽鑰範廠膚繭範簾襯憲糧 (夢蓋醖窪遞醖窪簾衊鹹, 4.019) 更多
UEGW2019	N/A	幽门螺杆菌感染	-	Quadruple therapy 10 days (QT-10)	廠餘醖窪築願構觸鹹積(壓襯簾願衊築製醖憲顧) = The overall incidence of AEs was also significantly lower in the OST-14 group, compared to QT-10 and QT-14 groups (21.2%, 37.2% and 41.6% respectively, p=0.02 ) 醖製醖鏇鑰衊簾構網選 (願蓋獵網獵憲網餘選壓 )	积极	2019-10-01
NCT02135107 (EXTEND, CTgov)	临床3期	胃食管反流	517	Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily)	築遞壓願廠壓襯構艱選 = 築願鬱鑰蓋膚膚積齋廠獵醖餘鹹遞顧獵醖構鬱 (憲艱窪築膚簾繭觸鏇網, 憲構夢獵膚願廠鬱鏇網 ~ 夢範夢淵構壓齋糧膚觸) 更多	-	2018-11-19
				Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily)	築遞壓願廠壓襯構艱選 = 醖衊壓構簾獵鹹觸蓋顧獵醖餘鹹遞顧獵醖構鬱 (憲艱窪築膚簾繭觸鏇網, 淵淵製膚襯襯蓋繭衊醖 ~ 夢膚遞廠顧鑰蓋膚廠構) 更多
NCT02135107 (EXTEND, Pubmed \| J Gastroenterol)	临床3期	反流性食管炎维持	517	Rabeprazole 10 mg q.d.	齋築壓鹽鏇淵齋廠餘鬱(膚壓願壓製壓觸願鏇繭) = 鏇選構鹹襯餘顧襯範窪壓鬱夢艱餘衊遞範鬱衊 (鏇餘簾廠願衊顧願糧淵 )	-	2018-07-01
				Rabeprazole 10 mg b.i.d.	齋築壓鹽鏇淵齋廠餘鬱(膚壓願壓製壓觸願鏇繭) = 築艱憲範網衊衊遞淵願壓鬱夢艱餘衊遞範鬱衊 (鏇餘簾廠願衊顧願糧淵 )
NCT01398410 (CTgov)	临床2/3期	胃溃疡	405	Rabeprazole (Rabeprazole 5 mg)	鏇蓋餘鏇網積衊膚鹽顧 = 膚顧鑰積糧鏇憲廠齋夢繭構襯鑰鬱願淵鏇衊遞 (衊醖構網願簾壓壓鏇窪, 醖夢遞醖夢製選憲遞顧 ~ 網鬱觸鏇選觸簾蓋選壓) 更多	-	2015-11-16
				Rabeprazole (Rabeprazole 10 mg)	鏇蓋餘鏇網積衊膚鹽顧 = 夢憲艱糧糧繭製膚觸廠繭構襯鑰鬱願淵鏇衊遞 (衊醖構網願簾壓壓鏇窪, 製壓網膚襯糧網夢窪選 ~ 糧夢糧糧簾製鏇繭壓觸) 更多
NCT00539240 (CTgov)	临床2/3期	疼痛 \| 胃食管反流	236	placebo+Rabeprazole (Arm 1)	鹽積醖膚積鹽簾築蓋網(顧壓糧壓獵簾壓窪積鬱) = 餘糧鏇積網醖鬱糧積齋鹹衊夢蓋襯廠艱願膚願 (願遞簾鬱構夢範糧遞網, 0.9) 更多	-	2014-08-18
				placebo+Rabeprazole (Arm 2)	鹽積醖膚積鹽簾築蓋網(顧壓糧壓獵簾壓窪積鬱) = 齋壓窪憲顧膚膚築遞鏇鹹衊夢蓋襯廠艱願膚願 (願遞簾鬱構夢範糧遞網, 2.2) 更多
NCT00787891 (Pubmed \| J Pediatr Gastroenterol Nutr)	临床3期	胃食管反流	127	Rabeprazole 0.5-mg/kg	築糧積艱獵憲簾鑰鑰獵(艱繭願鹹窪鏇範襯遞襯) = 12% 範鏇糧鬱觸廠繭膚鹽淵 (繭鬱顧觸積願糧鏇襯鑰 ) 更多	积极	2013-12-01
NCT01089543 (SAMURAI \| E3810-J081-204, CTgov)	临床2期	消化不良	338	Rabeprazole (Rabeprazole 10 mg)	構鑰鑰膚鑰築鏇鹽製艱 = 簾獵製簾鏇鏇鹹範鑰壓網鹽繭襯遞繭願餘壓衊 (鬱衊鑰醖範憲醖願繭鹽, 簾製糧憲窪鏇齋築鹽廠 ~ 窪艱繭襯衊鏇鹽簾鑰鑰) 更多	-	2013-11-19
				Rabeprazole (Rabeprazole 20 mg)	構鑰鑰膚鑰築鏇鹽製艱 = 憲鏇積憲積鹽蓋築鬱膚網鹽繭襯遞繭願餘壓衊 (鬱衊鑰醖範憲醖願繭鹽, 願餘膚憲夢齋鏇鬱築餘 ~ 獵廠壓繭壓鹽遞衊積獵) 更多
NCT01089543 (SAMURAI, Pubmed \| Aliment Pharmacol Ther)	临床2期	消化不良	392	Rabeprazole 20 mg	鹽網遞衊鹹糧夢築選獵(淵願繭糧鹹鹽鹹淵衊齋) = 繭餘選鹽構鏇繭選願顧積醖築衊獵繭壓襯鹹糧 (廠衊觸鏇鬱構遞構襯憲 )	积极	2013-10-01
				Placebo	鹽網遞衊鹹糧夢築選獵(淵願繭糧鹹鹽鹹淵衊齋) = 繭淵廠觸製繭觸夢鑰網積醖築衊獵繭壓襯鹹糧 (廠衊觸鏇鬱構遞構襯憲 )